Reuters: China say data show the US tire tariffs are unfair.
Reuters: A Fed policy debate has begun now that the recession is over.
Reuters: The world’s wealth is down 11% and the number of millionaires has fallen
Reuters: A pact between Bank of America (BAC) and the SEC was killed in court. Read More
The rate at which unemployment is growing has slowed recently and is no longer running more than 700,000 jobs lost a month. But, the firings are continuing, even at America’s largest companies, a sign that whatever bright light at the end of the economic tunnel, many firm’s don’t believe it is really there.
Eli Lilly (LLY) said it will let 5,500 people go. At the time of the announcement John C. Lechleiter, Ph.D., chairman and chief executive officer said, “The changes we are announcing today will accelerate the progress of the most exciting pipeline in our history, with more than 60 molecules currently in clinical development.” That gives the impression that management is upbeat about Lilly’s prospects. Read More
Diabetes is becoming an epidemic in the U.S. and the Western World. The ties to obesity are often direct, so the potential treatments are often directly tied as well. We did a recent dig down for the next $170 billion opportunity for eight different major diseases and conditions, and now we have conducted a much deeper dig down specifically in the field of diabetes over at BioHealthInvestor.com. We have recent and upcoming FDA action and data being presented from Novo Nordisk (NYSE: NVO), MannKind Corp. (NASDAQ: MNKD), Amylin Pharmaceuticals, Inc. (NASDAQ: AMLN), Eli Lilly (NYSE: LLY), Alkermes Inc. (NASDAQ: ALKS), Bristol-Myers Squibb (NYSE: BMY) and AstraZeneca (NYSE: AZN). There is a mini-race going on between some of the later stage studies from obesity and diabetes candidates from Arena Pharmaceuticals, Inc. (NASDAQ: ARNA), VIVUS, inc. (NASDAQ: VVUS), Orexigen Therapeutics, Inc. (NASDAQ: OREX) and Amylin Pharmaceuticals Inc. (NASDAQ: AMLN). Geron Corporation (NASDAQ: GERN) and StemCells Inc. (NASDAQ: STEM) were noted as two of the stem cell hopes, although stem cells may later rather than sooner.
Generex Biotechnology Corporation (NASDAQ: GNBT), Spherix Incorporated (NASDAQ: SPEX) and Oramed Pharmaceuticals Inc. (OTCBB: ORMP) were all noted in the much smaller or emerging plays. Home Diagnostics, Inc. (NASDAQ:HDIX) and Insulet Corporation (NASDAQ: PODD) have both recently had key events as the interest in test equipment companies continues to remain high.
FULL STORY with much more detail at BioHealthInvestor.com.
These are this Monday’s top day trader and active trader alert stocks. More detailed price and volume data is provided via a link to each story at VSInvestor.com:
Freddie Mac (NYSE: FRE) and Fannie Mae (NYSE: FNM) are going to likely be today’s top day trader stocks after Freddie Mac said the GSE doesn’t need money from Uncle Sam (for now). We expect 100 million shares.
Priceline.com inc. (NASDAQ: PCLN) is soaring to 52-week highs after better than expected earnings.
Research In Motion Ltd. (NASDAQ: RIMM) is down with a potential chart alert after UBS downgraded it.
Eli Lilly & Co. (NYSE: LLY) is down 3.5% and could get worse on an ugly downgrade from Goldman Sachs.
McDonald’s Corp. (NYSE: MCD) has a severe chart alert after its same store sales report.
TRW Automotive Holdings Corp. (NYSE: TRW) is down 7% on a secondary offering announcement.
YRC Worldwide Inc. (NASDAQ: YRCW) is one of the stronger stocks with 15% gains after another labor agreement was approved.
JON C. OGG
AUGUST 10, 2009
Safety and efficacy data are critical to drug candidates. But what really makes a potential drug attractive is strong top-line data, a new biotech-based treatment, and a massive potential market.
With help from Thomson Pharma and our own backlog of coverage, BioHealthInvestor.com, a 247wallst.com website, sought to find the most promising biopharmaceutical candidate from both biotech and pharmaceutical companies in each of the top 10 most prevalent medical conditions in the U.S. Read More
These are some of this morning’s top stocks to watch for active trading today based on pre-market and after-hours volume activity. There are links through to more detailed coverage and volume analysis at VSInvestor.com:
Alkermes Inc. (Nasdaq: ALKS) shares are ones to watch for volume upside following positive study results that may also affect shares of Eli Lilly & Co. (NYSE: LLY) and Sanofi Aventis (NYSE: SNY).
Merck & Co. (NYSE: MRK) shares are up over 3% after it beat EPS by 6 cents a share and reaffirmed fiscal 2009 guidance.
Spectrum Pharmaceuticals Inc. (Nasdaq: SPPI) shares are rising in premarket trade after getting FDA fast-track status for a bladder cancer candidate.
Lexmark International Group Inc. (NYSE: LXK) shares are ones to watch for volume downside after it missed expectations by 5 cents a share and guided Q3 EPS lower.
JDA Software Group Inc. (Nasdaq: JDAS) are ones to watch for volume upside after it posted a 17-cent a share EPS beat.
Idenix Pharmaceuticals Inc. (Nasdaq: IDIX) shares are ones to watch for volume downside after it missed EPS expectations by 3 cents a share.
Packaging Corp. of America (NYSE: PKG) shares are ones to watch for volume upside following a 12-cent EPS beat.
Boston Scientific (NYSE: BSX) is up strongly in early premarket trade on stronger-than-expected earnings.
CVB Financial Corp. (Nasdaq: CVBF) shares are ones to watch for downside after it announced a stock offering.
Werner Enterprises Inc. (Nasdaq: WERN) are ones to watch for volume downside on concerns about a revenue miss.
-The 24/7 Wall St. Team
Here are some of today’s top stories affecting key drug and biotech stocks, accompanied with links through to more detailed information and analysis at BioHealthInvestor.com:
New short-interest data suggest traders are now increasing their directional bets against biotech stocks. Pfizer Inc. (NYSE: PFE) and Merck & Co. (NYSE: MRK) are in the top 10 of all large-cap stocks with the greatest increase in the number of shares shorted.
Eli Lilly has the FDA’s OK to market its Effient blood thinner, but the black-box warning on its label is so strong that it’s hard to believe it can dent the market share of the Sanofi Aventis (NYSE: SNY)/ Bristol Myers Inc. (NYSE: BMY) drug Plavix.
OSI Pharmaceuticals Inc. (Nasdaq: OSIP) announced new data from its Phase III Saturn study of Tarceva, and it’s likely an incremental positive for the cancer drug over rival Eli Lilly & Co.’s (NYSE: LLY) drug Altima.
-The 24/7 Wall St. Team
These are some of the top stories affecting key drug and biotech stocks that are covered with more in-depth details and analysis this morning at BioHealthInvestor.com:
Amgen Inc’s (Nasdaq: AMGN)’s osteoporosis drug did so well in a head-to-head Phase III trial vs. the current standard drug from Novartis Inc. (NYSE: NVS) that the Amgen’s drug may become the new standard for patients with breast cancer.
Amylin Pharmaceuticals Inc. (Nasdaq: AMLN), along with partners Eli Lilly & Co. (NYSE: LLY) and Alkermes Inc. (Nasdaq: ALKS), announced its new drug application for a once-weekly version of Byetta will be reviewed by the FDA, which may help invigorate growth for the franchise.
Vical Inc. (Nasdaq: VICL) announced a positive four-month interim analysis for what is arguably its second-largest market opportunity, taking potentially another small step toward the goal of attracting a partner for its herpes vaccine program.
SciClone Pharmaceuticals Inc. (Nasdaq: SCLN) shares are down more than 7 percent on revenue and secondary offering fears. And Arena Pharmaceuticals Inc. (Nasdaq: ARNA) shares are falling after another dilutive offering.
Also, see our in-depth feature this week on five of the fastest-growing biotechs with improving analyst estimates: Alnylam Pharmaceuticals Inc. (Nasdaq: ALNY), Amicus Therapeutics Inc. (Nasdaq: FOLD), Halozyme Therapeutics Inc. (Nasdaq: HALO), American Oriental Bioengineering Inc. (NYSE: AOB), and Stemcells Inc. (Nasdaq: STEM).
-The 24/7 Wall St. Team
Underscoring just how much big pharma will depend on biotech acquisitions for future revenue, an analysis published by Evaluate Pharma today suggests half of the top 100 drugs worldwide by 2014 – and all of the top six — will be biotechs.
Three in the top six – the anticancer drugs Avastin, Rituxan and Herceptin, — are all made by Roche, which recently moved to acquire even more biotech drugs with its plans to acquire Genentech. Read More
We have compiled an updated lengthy 2009 American Society of Clinical Oncology, or ASCO, document showing many company cancer data presentations slated to start this weekend. This is broken down in drug and biotech companies with share values, ranges, and recent developments for the following drug and biotech companies: Abraxis BioScience, Inc. (NASDAQ:ABII), AEterna Zentaris Inc. (NASDAQ: AEZS), Allos Therapeutics, Inc. (NASDAQ: ALTH), Amgen Inc. (NASDAQ: AMGN), A.P. Pharma, Inc. (Nasdaq: APPA), Arqule Inc. (NASDAQ: ARQL), Bristol-Myers Squibb (NYSE: BMY), Celldex Therapeutics (NASDAQ: CLDX), Celgene Corporation (NASDAQ: CELG), Cell Therapeutics (NASDAQ: CTIC), Cougar Biotechnology, Inc. (NASDAQ: CGRB), Eli Lilly and Company (NYSE: LLY), Exelixis (NASDAQ: EXEL), Genomic Health, Inc. (NASDAQ: GHDX), GlaxoSmithKline (NYSE: GSK) , Immunogen (NASDAQ: IMGN), Medarex (NASDAQ: MEDX), Medivation, Inc. (NASDAQ: MDVN), Micromet, Inc. (NASDAQ: MITI), OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI), OSI Pharmaceuticals (NASDAQ: OSIP), Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM), Pfizer Inc. (NYSE: PFE), Rosetta Genomics (NASDAQ:ROSG), Synta Pharmaceuticals (NASDAQ: SNTA), Trubion Pharmaceuticals, Inc. (Nasdaq: TRBN), ZIOPHARM Oncology (NASDAQ: ZIOP), and ZymoGenetics, Inc. (NASDAQ: ZGEN).
The full presentation can be seen at BioHealthInvestor.com.
JON C. OGG
May 27, 2009
We are just about to get the first round of abstracts from companies presenting data at this year’s American Society of Clinical Oncology meeting for 2009. At BioHealthInvestor.com we compiled a brief summary for companies such as Abraxis BioScience, Inc. (NASDAQ:ABII), Allos Therapeutics, Inc. (NASDAQ: ALTH), Arqule Inc. (NASDAQ: ARQL), Celldex Therapeutics (NASDAQ: CLDX), Cell Therapeutics (NASDAQ: CTIC), Cougar Biotechnology, Inc. (NASDAQ: CGRB), Eli Lilly and Company (NYSE: LLY), Exelixis (NASDAQ: EXEL), Genomic Health, Inc. (NASDAQ: GHDX), GlaxoSmithKline (NYSE: GSK) , Immunogen (NASDAQ: IMGN), Medarex (NASDAQ: MEDX), Medivation, Inc. (NASDAQ: MDVN), OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI), OSI Pharmaceuticals (NASDAQ: OSIP), Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM), Pfizer Inc. (NYSE: PFE), Synta Pharmaceuticals (NASDAQ: SNTA), and ZIOPHARM Oncology (NASDAQ: ZIOP).
You can see that full pre-report here at BiohealthInvestor.com. As always be advised that there may be new sets of data released between now and the actual meeting from May 29 to June 2, 2009 in Orlando, Florida.
These are some of the top analyst downgrades and cautious research calls we have seen from Wall Street early this Tuesday morning:
Ansys (ANSS) Cut to Neutral from Overweight at JPMorgan.
Cabot (CBT) Cut to Underweight at JPMorgan.
Consolidated Edison (ED) Cut to Neutral at Credit Suisse.
Cullen/Frost Bankers (CFR) Cut to Underperform at Oppenheimer.
Duke Energy (DUK) Cut to Neutral at Credit Suisse.
Eli Lilly (LLY) Cut to Underperform at Leerink Swann.
Estee Lauder (EL) Cut to Sell at UBS.
General Growth Properties (GGP) Cut to Market Perform at Wachovia.
Headwater (HW) Cut to Hold at Canaccord Adams.
Intuitive Surgical (ISRG) Cut to Market Perform at Leerink Swann.
Omniture (OMTR) Cut to Hold at Citigroup.
Royal Bank of Scotland (RBS) Cut to Market Perform at Bernstein.
JON C. OGG
According to Reuters, government talk of auto company bankruptcy may cause creditors and the UAW to renew talks with GM (GM) and Chrysler.
Reuters reports that Obama is talking a hefty agenda with him to the G20.
Reuters writes that the US recession may not have bottomed.
Reuters reports that Obama is pitching an economic recovery to get a budget passed.
Reuters reports that Asia is split over disagreements between the US and China.
Reuters writes that the Chrysler tie-up with Fiat faces tough problems.
Reuters reports that Intel (INTC) rolled out a powerful new server chip.
Reuters reports that Morgan Stanley (MS) is completing a $6 billion property fund.
Reuters writes that Disney (DIS) will launch ad-supported channels on Google’s (GOOG) YouTube. Read More
These are te upgrades and positive research calls that we have seen from Wall Street this Wednesday morning:
JON C. OGG
According to Reuters, Steve Jobs will take a medical leave from Apple (AAPL) until June 30.
Reuters reports that Bank of America (BAC) is in discussions with the government to get billions of extra dollars.
Reuters reports that Western banks may regret rushing out of China.
There may be some speculation that drug giant Pfizer Inc. (NYSE: PFE) is looking at expansion through acquisitions. The FT reported that the world’s largest pharmaceutical company is willing to acquire a large rival drug company. It even cites the CEO as saying the company real goal is to grow revenue, which is different than many other goals out there from other peers in the new market. It also brings about the questions about who could be on the buyout target list.
According to Reuters, cities and states are facing shortfalls and potential defaults.
Reuters reports that the US steel industry is starting a "buy America" campaign.
Reuters reports that Fannie Mae (FNM) believes that IndyMac may owe it $1 billion.
Amylin Pharmaceuticals, Inc., (NASDAQ: AMLN) has been a battered biotech lately. But shares have just now gotten back above the single-digit threshold and are up more than 80% from recent lows. This morning Amylin and partner Eli Lilly & Co. (NYSE: LLY) announced that the US FDA feedback on the DURATION-1 study is appropriate to use as the basis for demonstrating comparability between intermediate-scale clinical trial material made in Alkermes’ (NASDAQ: ALKS) manufacturing facility, and commercial-scale drug product made at Amylin’s manufacturing facility.
These are some of the top pre-market analyst downgrades we are seeing this Friday morning:
Jon C. Ogg
October 10, 2008
According to Reuters, Bank of America (BAC) reported weak earnings and cut its dividend.
Reuters reports that Wells Fargo (WFC) and Citigroup (C) agreed to drop litigation for now and negotiate over a deal to buy Wachovia (WB).
Reuters reports that members of the Fed are divided on a rate cut.
| Today’s top tickerspy Indexes | |
| Home Furnishing R... | +14.1% |
| Ethanol and Biofu... | +5.1% |
| Electronics Retai... | +2.1% |
| Diabetes Stocks | +2.0% |
| Memory Chip Stock... | +2.0% |
 | |
| |
RSS Updates
Email Updates
